Proportion of participants reporting each solicited symptom during the 7-days after receipt of (first) vaccine dose.
- Thomas C. Darton (743526)
- Claire Jones (111487)
- Christoph J. Blohmke (231372)
- Claire S. Waddington (743527)
- Liqing Zhou (416094)
- Anna Peters (2902376)
- Kathryn Haworth (2993223)
- Rebecca Sie (2993226)
- Christopher A. Green (2993217)
- Catherine A. Jeppesen (2993214)
- Maria Moore (2993229)
- Ben A. V. Thompson (2993220)
- Tessa John (573745)
- Robert A. Kingsley (146912)
- Ly-Mee Yu (44961)
- Merryn Voysey (255058)
- Zoe Hindle (2993211)
- Stephen Lockhart (630618)
- Marcelo B. Sztein (159956)
- Gordon Dougan (30395)
- Brian Angus (225808)
- Myron M. Levine (130627)
- Andrew J. Pollard (44971)
Publication date
August 2016
DOIAbstract
<p>(A) Placebo, (B) M01ZH09, and (C) Ty21a vaccine recipient groups. Maximum severity score per participant for each symptom was used; grade 1: symptom reported but no interference with daily activity; grade 2: some interference with normal daily activities; grade 3: significant symptoms preventing normal daily activity; grade 4: potentially life-threatening (see <b><a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0004926#pntd.0004926.s003" target="_blank">S1 Protocol</a></b>).</p
Add to ORKG